BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials [Reuters]
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Reuters
BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials | Reuters Reuters Staff 1 Min Read Dec 5 (Reuters) - Revance Therapeutics Inc: * REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES * SAYS RT002 DELIVERED HIGHLY STATISTICALLY SIGNIFICANT REDUCTION IN SEVERITY OF GLABELLAR LINES AT WEEK 24 * SAYS RT002 DELIVERED POSITIVE TOP-LINE RESULTS IN ALLEVIATING MODERATE-TO-SEVERE GLABELLAR LINES IN 2 PIVOTAL SAKURA PHASE 3 TRIALS * SAYS RT002 APPEARED GENERALLY SAFE AND WELL-TOLERATED IN BOTH STUDIES * SAYS ASSUMING SUCCESSFUL COMPLETION OF SAKURA 3, COMPANY PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION IN FIRST HALF OF 2019 * SAYS LONG-TERM SAFETY TRIAL, SAKURA 3, IS FULLY ENROLLED AND IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2018 * SAYS COMPANY PLANS TO LAUNCH RT002 IN U.S. IN 2020, PENDING APPROVAL BY FDA Source text for Eikon: Further company coverage: All quotes de
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company [Yahoo! Finance]Yahoo! Finance
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingBusiness Wire
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
RVNC
Earnings
- 2/28/24 - Beat
RVNC
Sec Filings
- 4/17/24 - Form 4
- 4/9/24 - Form SC
- 3/21/24 - Form DEFA14A
- RVNC's page on the SEC website